RxDoctor Payments Data

Jyoti Pham, MD

Pain Medicine · Baton Rouge, LANPI 1093704181

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 194 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $843 and has fallen 71.7% since, to $239 in 2025. That places this record below the midpoint for pain medicine clinicians in LA, where the typical reported total is $3,650.

$3,650in general payments, 2019–2025

Across 194 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$571
  • Collegium Pharmaceutical, Inc.$423
  • Ipsen Biopharmaceuticals, Inc$411
  • Amgen$317
  • Microtransponder, Inc.$295
  • Merz Pharmaceuticals, LLC$227
  • plus $1K from 30 others

What the payments were for

  • Food & beverage$3,650100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,650 in reported general payments places this provider in the 50th percentile of 97 pain medicine providers in Louisiana.

See all pain medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$149,563
Medicare patients
267
Services billed
3,054

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SavellaMilnacipran Hcl36$15,798
Buprenorphine34$10,123
Tramadol Hcl ErTramadol Hcl127$9,990
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen409$6,457
Gabapentin357$4,573
Pregabalin180$3,285
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen271$2,435
Celecoxib104$2,424
Duloxetine Hcl154$2,334
Lidocaine23$2,218
Tizanidine Hcl194$2,046
Baclofen111$1,788
Tramadol Hcl240$1,188
Butorphanol Tartrate12$967
Nortriptyline Hcl47$870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSavella$571$15,79836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 97 pain medicine providers in Louisiana.

Other pain medicine in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →